The Silicon Review
Our primary goal is to offer a painless, non-invasive and effective skin cancer treatment, independent of tumor size, severity, and localization.
OncoBeta® GmbH is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies utilizing epidermal radioisotope applications. Headquartered at the Garching Technology and Founders Center GATE near Munich, OncoBeta® has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards. The Rhenium-SCT® is European CE certified and has filed for regulatory approval in several other countries outside the EU.
OncoBeta: Bringing back Quality of Life
Initially, OncoBeta was founded to further develop and commercialize its flagship product the Rhenium-SCT® (Skin Cancer Therapy). It is helping to redefine patient experiences, patient outcomes and expectations while redefining the approach to treating Non-Melanocytic Skin Cancer (NMSC), the most common cancer known. Patients suffering from NMSCs are often left with standard care options, which are either painful, non-aesthetically desired, or are invasive procedures in nature. OncoBeta is part of the story trying to rectify this.
OncoBeta has an extensive chain of customers, which includes the patient, the dermatologist or referring physician and the nuclear medicine physician. The patient is the end customer and therapy recipient and the dermatologist or referring physician prepares and refers the patient as well as performs follow-up on the treatment results. Then there is the nuclear medicine physician who performs the treatment. Each link in the chain is unique and has its own wants and needs which the company reviews continuously to ensure the best possible support.
With the patient in focus, OncoBeta works enthusiastically with medical, scientific, and industrial partners as well as local and national authorities to make this personalized, painless and non-invasive therapy accessible to patients all over the world. The Rhenium-SCT® significantly improves outcomes and the quality of life of non-melanoma skin cancer patients.
Challenges on the Stairway to Success
OncoBeta’s biggest challenge is to confront standard care options and its referral network, in order to provide patients with a more innovative therapeutic solution. Non-Melanocytic Skin Cancer (NMSC) treatment long referral chains, endowed interests, lack of patient focus and apprehension to innovation. These are some of the more pronounced inefficiencies characterizing the treatment of NMSCs.
OncoBeta is fighting from inside the healthcare apparatus to offer an improved alternative for those suffering from NMSCs. This means being highly active in the NMSC therapeutic community, exchanging in dialogues to revolutionize the perspectives of clinicians, to help clinicians become aware of standard care deficits and exchanging in dialogue to open referral chains to other therapeutic alternatives, such as the Rhenium-SCT®.
“This is the fight of all innovations in the marketplace, to challenge the status quo. This is our biggest challenge, but one worth pursuing with the patient’s perspective always in mind,” stated CEO of OncoBeta, Shannon D. Brown III.
Mr. Brown’s Advice for Maintaining Trust with Employees
“I try to listen to my colleagues being open to their ideas and letting them be a part of the decision-making process. I am also very honest with my team. I think it is only fair to give them my honest opinion and I expect theirs. If something isn’t going right or won’t work the way you thought, someone needs to tell you, no matter who that is. You can’t fix something if you don’t know what is broken. I treat everyone with the same dignity and respect that I expect and would like to receive. This and keeping your word builds and maintains trust.”
The Roadmap Ahead
OncoBeta presently services customers in Italy, Germany, South Africa and has now started treatments in Australia. The firm intends to expand its presence to the rest of Europe, Africa, North and South America, as well as the Asian markets in the months to come reaching out to physicians and healthcare institutions across the globe. “We are also working on our global footprint by not only expanding countries but are working on several new innovative applications as well. I am very thankful to have several healthcare patrons backing us with funds to propel cancer therapy efforts which also motivates my team,” said Shannon D. Brown III.
OncoBeta will further develop its innovative therapeutic applications with the use of modern radioisotopes and state-of-the-art application equipment achieving genuine added value with an extreme emphasis on ethical and economic criteria.
“My husband didn’t want to have another minor surgery for a lot of different reasons. While looking for alternative treatments we found the Rhenium-SCT®, he said it was worth a try and we are so glad he did! He read a book during treatment and went back to work the next day. No lost time at work, no pain, no anesthesia, it was all just too easy.”
“I did not go the doctor for a long time since I was afraid of the diagnosis and the therapy. A tumor on my cheek looked simply terrible. It was a hard time for my husband and me. Today the tumor is gone for good and I can enjoy life again.”
Shannon D. Brown III, CEO and Managing Director:
Shannon has a proven management track record and over 25 years of experience driving sales growth in the pharmaceutical and medical device industries. Shannon joined OncoBeta to assist in the transformation of the company from development to a commercial organization. Being a nine-time non-melanoma skin cancer survivor himself gives him not only the insight from the scientific point of view but also the needed patient perspective as well. He studied specialized emergency medicine with hospital administration at the US Army Academy of Health Sciences in Ft. Sam Houston, Texas. In his Military career, he had various assignments throughout the world where he managed field aid stations as well as medical clinics. After 10 years’ of military service, he focused his career on the pharmaceutical industry.
“Our mission is to continuously improve the quality of life of patients suffering from non-melanoma skin cancer, the world’s most common cancer.”